» Articles » PMID: 20397047

Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?

Overview
Journal Dig Dis Sci
Specialty Gastroenterology
Date 2010 Apr 17
PMID 20397047
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD).

Aim: The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD.

Methods: Separate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects.

Results: Most respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as "somewhat satisfied" to "completely dissatisfied" with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004).

Conclusions: Approximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.

Citing Articles

GERD: Latest update on acid-suppressant drugs.

Al-Frejat Z, Martini N, Esper A, Al-Frejat D, Younes S, Hanna M Curr Res Pharmacol Drug Discov. 2024; 7:100198.

PMID: 39282236 PMC: 11393603. DOI: 10.1016/j.crphar.2024.100198.


A scientometrics analysis and visualization of refractory gastroesophageal reflux disease.

Zhang N, Han M, Zheng Q, Zhang M, Zhi W, Li J Front Pharmacol. 2024; 15:1393526.

PMID: 39139634 PMC: 11319146. DOI: 10.3389/fphar.2024.1393526.


RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis.

Jeong Y, Lee B, Han S J Clin Med. 2024; 13(11).

PMID: 38892973 PMC: 11172701. DOI: 10.3390/jcm13113262.


Comparing the Safety and Efficacy of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in the Management of Patients With Peptic Ulcer Disease: A Systematic Review.

Begg M, Tarhuni M, Fotso M, Gonzalez N, Sanivarapu R, Osman U Cureus. 2023; 15(8):e44341.

PMID: 37779765 PMC: 10538946. DOI: 10.7759/cureus.44341.


Long-term potassium-competitive acid blockers administration causes microbiota changes in rats.

Najah H, Edelmuth R, Riascos M, Grier A, Al Asadi H, Greenberg J Surg Endosc. 2023; 37(10):7980-7990.

PMID: 37452210 DOI: 10.1007/s00464-023-10269-6.


References
1.
Calabrese C, Fabbri A, Di Febo G . Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging. 2007; 2(1):85-92. PMC: 2684091. DOI: 10.2147/ciia.2007.2.1.85. View

2.
Vakil N . Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004; 19(10):1041-9. DOI: 10.1111/j.1365-2036.2004.01957.x. View

3.
Sandler R, Everhart J, Donowitz M, Adams E, Cronin K, Goodman C . The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 122(5):1500-11. DOI: 10.1053/gast.2002.32978. View

4.
Armstrong D . Systematic review: persistence and severity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008; 28(7):841-53. DOI: 10.1111/j.1365-2036.2008.03804.x. View

5.
Rubenstein J, Nojkov B, Korsnes S, Adlis S, Shaw M, Weinman B . Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007; 26(3):443-52. DOI: 10.1111/j.1365-2036.2007.03393.x. View